|
|
Line 335: |
Line 335: |
| <td><a href="http://parts.igem.org/Part:BBa_K2036029"> BBa_K2036029 </a></td> | | <td><a href="http://parts.igem.org/Part:BBa_K2036029"> BBa_K2036029 </a></td> |
| <td>PP2CA-TTADH1-pCyc-Kozak-Snrk2.2-TTADH1-pCyc-Kozak-ABF2-TTADH1-prd29A-Kozak-GFP-LVAssrAtag </td> | | <td>PP2CA-TTADH1-pCyc-Kozak-Snrk2.2-TTADH1-pCyc-Kozak-ABF2-TTADH1-prd29A-Kozak-GFP-LVAssrAtag </td> |
− | <td> To characterize PP2CA’s interaction with ABF2,which means the whole circuit functional verification. </td> | + | <td> To characterize PP2CA’s interaction with ABF2,which means the whole circuit functional verification. </td> |
| </tr> | | </tr> |
| </table> | | </table> |
Line 349: |
Line 349: |
| <td><a href="http://parts.igem.org/Part:BBa_K2036024"> BBa_K2036024 </a></td> | | <td><a href="http://parts.igem.org/Part:BBa_K2036024"> BBa_K2036024 </a></td> |
| <td> placm-pRE-RBS-Cro-RBS-CII-TT-patp2-RBS-CI-TT-pR-RBS-CIII-RBS-iLDH-TT-pRM-RBS-beta-galactosidase </td> | | <td> placm-pRE-RBS-Cro-RBS-CII-TT-patp2-RBS-CI-TT-pR-RBS-CIII-RBS-iLDH-TT-pRM-RBS-beta-galactosidase </td> |
− | <td> The whole circuit of the application for lactose intolerance therapy. </td> | + | <td> The whole circuit of the application for lactose intolerance.</td> |
| </tr> | | </tr> |
| </table> | | </table> |